Skip to main content

Table 2 Mean (standard deviation) values at baseline and 12 months after the Can Do treatment with relative difference (percentage of baseline) (mean, standard error of the mean) and P value for comparison (paired t-test) for self-efficacy [multiple sclerosis self-efficacy scale (MSSES)], impact on participation and autonomy [impact on participation and autonomy questionnaire (IPA)], HRQoL [multiple sclerosis quality of life-54 items (MSQoL-54)], anxiety and depression [Hospital anxiety and depression scale (HADS)], and fatigue [(modified fatigue impact scale-5 items (MFIS-5)] in the progressive group (N = 14); Δ, difference

From: Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later

Progressive group (N = 14) Baseline 12th month % Δ P
MSSES function (N = 13) 56.24 (22.36) 53.65 (25.55) −5.34 (5.34) 0.438
MSSES control (N = 13) 47.80 (15.00) 52.78 (20.01) +7.96 (8.15) 0.297
IPA limitations (N = 14) 2.76 (0.68) 2.72 (0.66) −0.30 (6.45) 0.720
IPA problems (N = 14) 1.90 (0.34) 1.84 (0.46) −1.58 (6.48) 0.631
MSQoL-54 physical (N = 5) 38.12 (6.46) 45.54 (18.12) +4.18 (13.05) 0.719
MSQoL-54 mental (N = 10) 53.83 (17.32) 57.03 (14.29) +8.06 (9.51) 0.649
HADS anxiety (N = 13) 7.21 (3.38) 6.31 (4.55) −6.99 (12.78) 0.477
HADS depression (N = 14) 6.71 (3.89) 6.50 (3.78) +25.59 (25.11) 0.843
MFIS-5 (N = 14) 12.57 (4.03) 11.93 (3.36) −1.00 (6.60) 0.395